Artificial intelligence is reshaping pharmaceutical research, and VERAXA Biotech (NASDAQ: VRXA) is positioning itself to capitalize on this trend through a strategic partnership with AI-focused contract research organization Ardigen. The collaboration aims to strengthen development of VERAXA’s BiTAC(R) oncology platform by leveraging AI-enabled target discovery and validation, as announced in a press release.
The partnership combines VERAXA’s antibody engineering capabilities with Ardigen’s expertise in artificial intelligence, computational biology and bioinformatics. Ardigen, headquartered in Kraków, Poland, with U.S. operations in San Francisco, has supported more than 700 discovery projects. The collaboration focuses on identifying optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while reducing development risks.
VERAXA’s Boolean “AND-gated” BiTAC(R) technology presents a use case particularly well suited for AI-assisted target selection and therapeutic design. By analyzing historical clinical and preclinical datasets, AI can help identify promising targets that were previously abandoned due to safety concerns, potentially reviving abandoned drug candidates. This approach aligns with a broader industry trend toward combining computational biology with next-generation antibody therapeutics to improve research productivity.
Major pharmaceutical companies are expanding AI collaborations across oncology and immunology, underscoring the growing importance of machine learning in drug discovery. AI tools can analyze complex biological data, identify drug targets and improve clinical development decisions. For VERAXA, the partnership could accelerate the development of its BiTAC(R) platform, which designs novel cancer therapies.
The announcement comes amid increasing adoption of AI in drug R&D, with the potential to reduce costs and timelines. By integrating AI into its workflow, VERAXA may enhance its ability to discover and validate targets more efficiently than traditional methods. This could give the company a competitive edge in the crowded oncology space.
Investors should note that forward-looking statements in the announcement involve risks and uncertainties, as detailed in VERAXA’s SEC filings. The company undertakes no duty to update this information unless required by law. For more details, refer to the full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
